GlassScriptPhysician profile
Michael K Landi
NPI 1437116308
$5,012.46
in general payments reported to CMS, 2019-2025
39 companies · $418 in 2025
The $418 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $397 · 2021: $890 · 2022: $902 · 2023: $1,660 · 2024: $391 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.16 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,105.71 | 2019-2023 | Octrode |
| Flospine LLC | $1,000.00 | 2023 | Expandable Tlif System |
| Boston Scientific Corporation | $648.81 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $621.31 | 2021-2023 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $323.29 | 2021-2025 | Xtampza, Belbuca |
| Choice Spine, LLC | $139.22 | 2025 | Stratofuse, Blackhawk Cervical Spacer System, Triton |
| Scilex Pharmaceuticals INC. | $96.26 | 2019-2024 | |
| Si-Bone, INC. | $82.13 | 2021-2024 | |
| Eisai INC. | $75.44 | 2025 | |
| Zimmer Biomet Holdings, INC. | $70.22 | 2019 | |
| Amgen INC. | $66.87 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $65.44 | 2021-2023 | Hetlioz |
| Lilly USA, LLC | $62.65 | 2019-2025 | Amyvid, Kisunla |
| Merck Sharp & Dohme LLC | $60.60 | 2019-2024 | Bridion |
| Lundbeck LLC | $56.08 | 2024-2025 | Vyepti |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.39 | 2019 | |
| Abbvie INC. | $39.55 | 2022-2023 | |
| Biogen, INC. | $37.14 | 2021-2024 | Tysabri, Vumerity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.36 | 2021-2024 | Relistor |
| Foundation Fusion Solutions, LLC | $34.02 | 2024-2025 | |
| Celgene Corporation | $30.16 | 2025 | Zeposia |
| Sk Life Science, INC. | $26.67 | 2024 | |
| Stryker Corporation | $23.38 | 2022 | |
| Emd Serono, INC. | $22.59 | 2025 | |
| Ucb, INC. | $21.35 | 2023 | Nayzilam |
| Grifols USA, LLC | $19.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.57 | 2025 | |
| Almatica Pharma LLC | $17.28 | 2023 | Gralise |
| Mdd US Operations, LLC | $17.05 | 2022 | |
| Pfizer INC. | $16.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.81 | 2020 | |
| Zyla Life Sciences, INC. | $15.65 | 2019 | |
| Depuy Synthes Sales INC. | $15.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.63 | 2021 | |
| Assertio Therapeutics, INC. | $14.45 | 2019 | |
| Virtus Pharmaceuticals LLC | $13.93 | 2021 | |
| Banner Life Sciences, LLC | $12.43 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.70 | 2019 | |
| Promius Pharma LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Landi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.